Aeviant Biosciences is a therapeutics company designing medicines around biological state. Founded in 2026, Aeviant is based in British Columbia, Canada.
Aeviant starts with a disease-linked failure in physiological control. Each program defines the therapeutic response required in the relevant tissues, signals and points in time. That requirement guides target selection, modality, molecular design and the evidence needed to advance toward a medicine.
AVX-1 is Aeviant’s lead therapeutic program. It is currently in computational design, where molecular hypotheses are challenged against the program’s state-dependent requirements and prioritized for synthesis and experimental pharmacology.
Further information will be disclosed after the relevant patent filing. Until then, program details remain confidential.